Global Deafness Gene Detection Kits Market Size, Share, and COVID-19 Impact Analysis, By Type (Real-Time PCR, Microarray Chip Method, and Others), By Application (Adult Detection and Newborn Detection), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Deafness Gene Detection Kits Market Insights Forecasts to 2033

• The Global Deafness Gene Detection Kits Market Size was Estimated at USD 0.212 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 4.04% From 2023 to 2033
• The Worldwide Deafness Gene Detection Kits Market Size is Expected to reach USD 0.315 Billion By 2033
• Asia Pacific is predicted to Grow at the Fastest CAGR throughout the projection period

The Global Deafness Gene Detection Kits Market Size is predicted to exceed USD 0.315 Billion by 2033, Growing at a CAGR of 4.04% from 2023 to 2033.

Market Overview

The deafness gene detection kits market involves the manufacturing and distribution of diagnostic tools that are used to identify genetic mutations associated with hearing loss or deafness. An example of a deafness gene detection kit is the Hearing Loss Susceptibility Geno Array Diagnostic Kit is a rapid, high-throughput screening tool for hotspot mutations related to hereditary hearing loss. It evaluates thirteen mutations in four genes, enabling early diagnosis and prevention of certain antibiotics. In China, 27.8 million people have hearing disabilities, accounting for 33% of the total number. Over 30,000 new deaf children are born each year, with over 60% of genetic factors causing deafness. Environmental factors, unknown factors, and deaf gene mutations affect over 80 million people. Many patients with late hearing loss are genetically influenced, resulting in sensitivity to deafening environmental factors and disease-causing deafness. Traditional detection methods cannot detect deafness caused by late deafness or gene mutations in time, making testing deafness crucial for early diagnosis, detection, and intervention.

According to the World Health Organization (WHO) Over 430 million people, including 34 million children, or more than 5% of the global population, need rehabilitation to treat their debilitating hearing loss. According to projections, one in ten people, or over 700 million people, would have a debilitating hearing loss by 2050. Hearing loss in the better hearing ear that is greater than 35 decibels (dB) is referred to be disabling hearing loss. Almost 80% of those who suffer from debilitating hearing loss reside in low- and middle-income nations. As people age, hearing loss becomes more common; among people over 60, more than 25% have debilitating hearing loss. The growing need for early diagnosis of hearing impairments is driving the importance of gene detection kits, which enable healthcare providers to identify specific genetic mutations, thereby improving patient outcomes.

Report Coverage

This research report categorizes the global deafness gene detection kits market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global deafness gene detection kits market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global deafness gene detection kits market.

Driving Factors:

Increasing cases of hearing loss:

Hearing loss is the most common sensory deficit worldwide and can be conductive, sensorineural, or mixed. Conductive hearing loss disrupts sound wave transmission to the cochlea, with common causes including abnormal auricle formation, cerumen impaction, ear canal foreign bodies, otitis externa, ossicular chain dysfunction, and middle ear effusion. Sensorineural hearing loss (SNHL) results from problematic transmission of stimuli at or after the cochlea, possibly due to hair cell dysfunction or eighth nerve disorder. In pediatrics, genetic causes account for over 50% of hearing loss, with non-syndromic genetic hearing loss. Hearing loss affects 0.5 to 1% of children in the United States and can be profound, mild, or moderate. Factors like aging populations, noise pollution, and unsafe listening practices contribute significantly. Age-related hearing loss (presbycusis) becomes more common, particularly among those over 60 years old. Over 1 billion young adults are at risk of permanent hearing loss due to unsafe listening habits.

Development in the field of genetic research:

A promising cure for hearing loss is gene therapy, especially for inherited variants, which make up over 50% of cases. In an attempt to replace or repair damaged genes, certain genes must be introduced into cells. It has been effective in assisting animals with hereditary hearing loss to regain their hearing in animal experiments. The market for deafness gene detection kits is growing as a result of advances in genetic research, which fuel the demand for sophisticated gene detection kits. For the first time, comprehensive genetic testing is now accessible owing to the rapid gene discovery for deafness made feasible by massively parallel sequencing methods.

Restraining Factors

The lack of established standards, the high cost of sophisticated genetic testing techniques, and the complexity of interpreting results prevent widespread adoption, enabling companies in the sector to invest in infrastructure development, education, and training may hinder the market growth.

Market Segmentation

The global deafness gene detection kits market share is classified into type and application.

• The real-time PCR segment dominated the global deafness gene detection kits market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the type, the global deafness gene detection kits market is categorized into real-time PCR, microarray chip method, and others. Among these, the real-time PCR segment dominated the global deafness gene detection kits market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segment growth is attributed to the minimized risk of errors, faster process, highly sensitive, enhanced specificity, precise assessment of the PCR products, utilizes the lower concentration of targeted DNA or RNA, reproducibility, and ease of handling.

• The newborn detection segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the application, the global deafness gene detection kits market is categorized into adult detection and newborn detection. Among these, the newborn detection segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is attributed to early diagnosis, technological innovations, provides particular insights regarding the cause of deafness, the rising prevalence of hearing loss in neonates and infants, and genetic mutations leading to hearing loss in newborns which leads to an increase in screening activities of the deafness.

Regional Segment Analysis of the Global Deafness Gene Detection Kits Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global deafness gene detection kits market over the predicted timeframe.

North America is anticipated to hold the largest share of the global deafness gene detection kits market over the predicted timeframe. The region's growth is fueled by a prominent healthcare infrastructure, rapid adoption of advanced diagnostic technologies, favorable reimbursement policies, robust research and development activities, and the presence of major market players. The United States is a significant market, with a high prevalence of genetic hearing loss and robust healthcare spending, driven by innovative medical care infrastructure, extensive research and development initiatives, and widespread genetic testing practices. The region's utilization of Deafness Gene Detection Kits is projected to be significantly driven by the active participation of key market players and favorable reimbursement policies.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The growing prevalence of hereditary diseases, increasing awareness, and rising medical expenses are the primary drivers of development. In this region, China, Japan, and India constitute significant markets. The sector is expanding as a result of government initiatives that promote genetic screening programs, expanding medical facilities, and rapid growth in the economy. The area provides market participants with several opportunities to increase their environmental impact and capitalize on the rising need for genetic testing products.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global deafness gene detection kits market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Centogene N.V.
• Thermo Fisher Scientific Inc.
• PerkinElmer, Inc.
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Bio-Rad Laboratories, Inc.
• Pacific Biosciences of California, Inc.
• Genomic Vision
• Invitae Corporation
• Illumina, Inc.
• Becton, Dickinson and Company
• Natera, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2024, Genedrive plc, a pharmacogenetic testing company, received Breakthrough Device Designation from the U.S. Food and Drug Administration for its MT-RNR1 ID Kit. This rapid point-of-care test screens infants for a genetic variant that can cause life-long hearing loss when given certain antibiotics. Infants identified with the variant can be given alternative antibiotics, potentially saving thousands of children from hearing loss and providing a net positive financial outcome case to healthcare systems.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global deafness gene detection kits market based on the below-mentioned segments:

Global Deafness Gene Detection Kits Market, By Type

• Real-Time PCR
• Microarray Chip Method
• Others

Global Deafness Gene Detection Kits Market, By Application

• Adult Detection
• Newborn Detection

Global Deafness Gene Detection Kits Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • 'Rest of the Middle East & Africa